New to Investing? This 1 Medical Stock Could Be the Perfect Starting Point
https://www.zacks.com/stock/news/2282603/new-to-investing-this-1-medical-stock-could-be-the-perfect-starting-point?cid=CS-ZC-FT-tale_of_the_tape|zacks_education_focus_list-2282603
Jun 03, 2024 - Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Focus List.
0
This Is the Biggest Risk for Eli Lilly and Novo Nordisk Investors
https://www.fool.com/investing/2024/06/01/this-biggest-risk-for-eli-lilly-and-novo-nordisk/?source=iedfolrf0000001
Jun 01, 2024 - These stocks are trading at sky-high valuations which could make them vulnerable to sell-offs.
0
A New Name in Weight Loss Drugs
https://www.fool.com/investing/2024/05/28/a-new-name-in-weight-loss-drugs/?source=iedfolrf0000001
May 28, 2024 - Novo Nordisk and Eli Lilly have soared on the popularity of GLP-1 weight loss drugs. Now Hims & Hers is trying to get in on the action with a more available and affordable option.
0
Beat the Market the Zacks Way: EverQuote, Micron, Amgen in Focus
https://www.zacks.com/stock/news/2279920/beat-the-market-the-zacks-way-everquote-micron-amgen-in-focus?cid=CS-ZC-FT-analyst_blog|investment_ideas-2279920
May 28, 2024 - Our time-tested methodologies were at work to help investors navigate the market well last week. Here are some of our key performance data from the past three months.
0
Eli Lilly (LLY) to Ramp Up Indiana Site for Mounjaro, Zepbound
https://www.zacks.com/stock/news/2279236/eli-lilly-lly-to-ramp-up-indiana-site-for-mounjaro-zepbound?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2279236
May 27, 2024 - Since 2020, Eli Lilly (LLY) has committed more than $18 billion to building new manufacturing sites as well as updating existing manufacturing facilities.
0
Top Research Reports for Novo Nordisk, QUALCOMM & Caterpillar
https://www.zacks.com/commentary/2277328/top-research-reports-for-novo-nordisk-qualcomm-caterpillar?cid=CS-ZC-FT-research_daily-2277328
May 22, 2024 - Today's Research Daily features new research reports on 16 major stocks, including Novo Nordisk (NVO), QUALCOMM (QCOM) and Caterpillar (CAT), as well as two micro-cap stocks CSP Inc. (CSPI) and Epsilon Energy Ltd. (EPSN).
0
Play These New ETFs to Tap Lucrative Weight Loss Drug Market
https://www.zacks.com/stock/news/2277076/play-these-new-etfs-to-tap-lucrative-weight-loss-drug-market?cid=CS-ZC-FT-etf_news_and_commentary-2277076
May 22, 2024 - Global obesity rates have nearly tripled since 1975, per WHO and Goldman Sachs. The growing usage of GLP-1 drugs in weight management now makes the industry a thriving one.
0
Pharma Stock Roundup: BAYRY's Q1 Earnings, JNJ's New Buyout, Pipeline Updates
https://www.zacks.com/stock/news/2275562/pharma-stock-roundup-bayry-s-q1-earnings-jnj-s-new-buyout-pipeline-updates?cid=CS-ZC-FT-analyst_blog|stock_roundup-2275562
May 17, 2024 - Bayer (BAYRY) releases Q1 results. J&J (JNJ) set to acquire private biotech, Proteologix, which will add atopic dermatitis candidates.
0
Meet the GLP-1 Drug That Could Be the Biggest Concern for Eli Lilly and Novo Nordisk
https://www.fool.com/investing/2024/05/17/meet-the-glp-1-drug-that-could-be-the-biggest-conc/?source=iedfolrf0000001
May 17, 2024 - Could Amgen be the next stock to soar due to a GLP-1 drug?
0
Roche (RHHBY) Posts Encouraging Phase I Obesity Drug Data
https://www.zacks.com/stock/news/2274860/roche-rhhby-posts-encouraging-phase-i-obesity-drug-data?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2274860
May 16, 2024 - Data from the study shows that nearly half of the patients who received Roche's (RHHBY) subcutaneously-administered obesity drug lost more than 20% of their body weight after 24 weeks.
0